{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:13:59Z","timestamp":1788369239251,"version":"build-2803163510"},"reference-count":41,"publisher":"Bioscientifica","issue":"3","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intestinal barrier dysfunction and gut microbiota dysbiosis contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). However, the effects of empagliflozin on the gut microbiota\u2013intestinal barrier axis remain incompletely understood. This study investigated whether empagliflozin improves intestinal barrier integrity and gut microbiota profiles in a streptozotocin (STZ)-induced murine model of T2DM. Male C57BL\/6 mice were fed a high-fat diet followed by STZ injection to induce T2DM and then treated with empagliflozin (10 mg\/kg\/day) for 8 weeks. Intestinal barrier-related proteins were assessed by immunofluorescence and western blotting. Gut microbial profiles were analyzed using 16S rRNA gene sequencing. Short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and inflammatory cytokines were quantified by GC\u2013MS and ELISA. Empagliflozin treatment significantly reduced fasting blood glucose levels and attenuated weight gain in diabetic mice. Diabetic animals exhibited compromised intestinal barrier structure, accompanied by decreased tight junction protein expression (Claudin-1 and ZO-1) and enhanced TLR4\/MyD88\/NF-\u03baB signaling, which were substantially alleviated following empagliflozin treatment. Concurrently, elevated inflammatory cytokines (IL-1\u03b2, IL-6, and TNF-\u03b1) and LPS levels were significantly reduced following empagliflozin treatment. Microbiome analyses revealed treatment-associated reorganization of gut microbial communities, including altered \u03b2-diversity patterns, shifts in diabetes-related taxa, and modified microbial interaction networks. In addition, empagliflozin increased fecal concentrations of key SCFAs, particularly butyrate and isohexanoate. Empagliflozin was associated with improved metabolic parameters, enhanced intestinal barrier integrity, reduced inflammation, and alterations in gut microbiota composition and predicted metabolic activity. Modulation of gut homeostasis may contribute to the therapeutic benefits of empagliflozin in T2DM.<\/jats:p>","DOI":"10.1530\/joe-26-0110","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:59:58Z","timestamp":1787133598000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-5","source":"Crossref","is-referenced-by-count":0,"title":["Empagliflozin improves gut microbial disturbances and intestinal barrier integrity in STZ-induced type 2 diabetic mice"],"prefix":"10.1530","volume":"270","author":[{"given":"Ying","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Chongqing General Hospital, Chongqing University 1 , ,","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University 2 , ,","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chongqing Medical University 3 , ,","place":["Chongqing, China"]},{"name":"Department of Pathology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital 4 , ,","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chongqing Medical University 3 , ,","place":["Chongqing, China"]},{"name":"Institute of Pathology and Southwest Cancer Center, First Affiliated Hospital, Army Medical University 5 , ,","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-6747","authenticated-orcid":true,"given":"Gangyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University 2 , ,","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, General Hospital of Central Theater Command 6 , ,","place":["Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-3625","authenticated-orcid":true,"given":"Mingyuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University 2 , ,","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026090212264547600_bib1","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00125-025-06478-4","article-title":"Variation in type 2 diabetes prevalence across different populations: the key drivers","volume":"68","author":"Gong","year":"2025","journal-title":"Diabetologia"},{"key":"2026090212264547600_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101507","article-title":"Gut microbiome, prebiotics, intestinal permeability and diabetes complications","volume":"35","author":"Snelson","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026090212264547600_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cmet.2020.06.011","article-title":"The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study","volume":"32","author":"Wu","year":"2020","journal-title":"Cell Metab"},{"key":"2026090212264547600_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diabet.2016.09.004","article-title":"Increased intestinal permeability as a risk factor for type 2 diabetes","volume":"43","author":"Cox","year":"2017","journal-title":"Diabetes Metab"},{"key":"2026090212264547600_bib5","doi-asserted-by":"crossref","first-page":"bvz039","DOI":"10.1210\/jendso\/bvz039","article-title":"Intestinal barrier dysfunction, LPS translocation, and disease development","volume":"4","author":"Ghosh","year":"2020","journal-title":"J Endocr Soc"},{"key":"2026090212264547600_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/metabo15060397","article-title":"Gut microbiota dysbiosis and its impact on type 2 diabetes: from pathogenesis to therapeutic strategies","volume":"15","author":"Yu","year":"2025","journal-title":"Metabolites"},{"key":"2026090212264547600_bib7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/ijms23031105","article-title":"Gut microbiota and short chain fatty acids: implications in glucose homeostasis","volume":"23","author":"Portincasa","year":"2022","journal-title":"IJMS"},{"key":"2026090212264547600_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI88879","article-title":"Immunologic impact of the intestine in metabolic disease","volume":"127","author":"Winer","year":"2017","journal-title":"J Clin Investig"},{"key":"2026090212264547600_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/nu16020269","article-title":"Nutrition at the intersection between gut microbiota eubiosis and effective management of type 2 diabetes","volume":"16","author":"Hamamah","year":"2024","journal-title":"Nutrients"},{"key":"2026090212264547600_bib10","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/clinem\/dgac210","article-title":"Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes","volume":"107","author":"Deng","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090212264547600_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105816","article-title":"Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice","volume":"26","author":"Shi","year":"2023","journal-title":"iScience"},{"key":"2026090212264547600_bib12","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v16.i4.102970","article-title":"Characteristic dysbiosis in patients with type 2 diabetes and hyperuricemia, and the effect of empagliflozin on gut microbiota","volume":"16","author":"Deng","year":"2025","journal-title":"World J Diabetes"},{"key":"2026090212264547600_bib13","article-title":"Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice","volume":"12","author":"Yang","year":"2024","journal-title":"PeerJ"},{"key":"2026090212264547600_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2093171","article-title":"Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study","volume":"2016","author":"Yan","year":"2016","journal-title":"J Diabetes Res"},{"key":"2026090212264547600_bib15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","article-title":"Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2","volume":"37","author":"Bolyen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026090212264547600_bib16","article-title":"MicrobiotaProcess: a comprehensive R package for deep mining microbiome","volume":"4","author":"Xu","year":"2023","journal-title":"Innovation"},{"key":"2026090212264547600_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","article-title":"PICRUSt2 for prediction of metagenome functions","volume":"38","author":"Douglas","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2026090212264547600_bib18","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1002\/imt2.32","article-title":"ggClusterNet: an R package for microbiome network analysis and modularity-based multiple network layouts","volume":"1","author":"Wen","year":"2022","journal-title":"iMeta"},{"key":"2026090212264547600_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1655522","article-title":"Sitagliptin ameliorates microbial dysbiosis and enhances gut barrier integrity in streptozotocin-induced type 2 diabetic rats","volume":"16","author":"Chang","year":"2025","journal-title":"Front Microbiol"},{"key":"2026090212264547600_bib20","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/gb-2011-12-6-r60","article-title":"Metagenomic biomarker discovery and explanation","volume":"12","author":"Segata","year":"2011","journal-title":"Genome Biol"},{"key":"2026090212264547600_bib21","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/bioinformatics\/btu494","article-title":"STAMP: statistical analysis of taxonomic and functional profiles","volume":"30","author":"Parks","year":"2014","journal-title":"Bioinformatics"},{"key":"2026090212264547600_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jad.2024.05.150","article-title":"Empagliflozin alleviates neuroinflammation by inhibiting astrocyte activation in the brain and regulating gut microbiota of high-fat diet mice","volume":"360","author":"Huang","year":"2024","journal-title":"J Affect Disord"},{"key":"2026090212264547600_bib23","article-title":"Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota","volume":"1867","author":"Deng","year":"2022","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids"},{"key":"2026090212264547600_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/1440-1681.13842","article-title":"Empagliflozin attenuates liver fibrosis in high-fat diet\/streptozotocin-induced mice by modulating gut microbiota","volume":"51","author":"Huang","year":"2024","journal-title":"Clin Exp Pharma Physio"},{"key":"2026090212264547600_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117277","article-title":"Empagliflozin alleviates doxorubicin-induced myocardial injury by inhibiting RIP3-dependent TLR4\/MyD88\/NF-\u03baB signaling pathway","volume":"242","author":"Zou","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"2026090212264547600_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10787-023-01227-8","article-title":"Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis","volume":"32","author":"Makaro","year":"2024","journal-title":"Inflammopharmacol"},{"key":"2026090212264547600_bib27","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/cells11193107","article-title":"Anti-inflammatory properties of the SGLT2 inhibitor empagliflozin in activated primary microglia","volume":"11","author":"Heimke","year":"2022","journal-title":"Cells"},{"key":"2026090212264547600_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0126-x","article-title":"Mechanisms regulating intestinal barrier integrity and its pathological implications","volume":"50","author":"Chelakkot","year":"2018","journal-title":"Exp Mol Med"},{"key":"2026090212264547600_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/advances\/nmz061","article-title":"Negative effects of a high-fat diet on intestinal permeability: a review","volume":"11","author":"Rohr","year":"2020","journal-title":"Adv Nutr"},{"key":"2026090212264547600_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2025.114838","article-title":"The role of gut microbiota and bacterial translocation in the pathogenesis and management of type 2 diabetes mellitus: mechanisms, impacts, and dietary therapeutic strategies","volume":"293","author":"Murugesan","year":"2025","journal-title":"Physiol Behav"},{"key":"2026090212264547600_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1084702","article-title":"Relationship between changes in microbiota induced by resveratrol and its anti-diabetic effect on type 2 diabetes","volume":"9","author":"Fernandez-Quintela","year":"2023","journal-title":"Front Nutr"},{"key":"2026090212264547600_bib32","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3389\/fmicb.2018.01953","article-title":"Probiotic Lactobacillus plantarum promotes intestinal barrier function by strengthening the epithelium and modulating gut microbiota","volume":"9","author":"Wang","year":"2018","journal-title":"Front Microbiol"},{"key":"2026090212264547600_bib33","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1039\/C9FO01062A","article-title":"Lactobacillus acidophilus alleviates type 2 diabetes by regulating hepatic glucose, lipid metabolism and gut microbiota in mice","volume":"10","author":"Yan","year":"2019","journal-title":"Food Funct"},{"key":"2026090212264547600_bib34","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1007\/s11357-024-01250-9","article-title":"Empagliflozin rescues lifespan and liver senescence in naturally aged mice","volume":"46","author":"Long","year":"2024","journal-title":"Geroscience"},{"key":"2026090212264547600_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41575-022-00631-9","article-title":"Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms","volume":"19","author":"Cani","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026090212264547600_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.1984104","article-title":"Akkermansia muciniphila : is it the Holy Grail for ameliorating metabolic diseases?","volume":"13","author":"Yan","year":"2021","journal-title":"Gut Microbes"},{"key":"2026090212264547600_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.11.051","article-title":"Role of gut microbiota in type 2 diabetes pathophysiology","volume":"51","author":"Gurung","year":"2020","journal-title":"EBioMedicine"},{"key":"2026090212264547600_bib38","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1161\/CIRCULATIONAHA.118.033714","article-title":"Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis","volume":"138","author":"Yoshida","year":"2018","journal-title":"Circulation"},{"key":"2026090212264547600_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13104-021-05466-2","article-title":"Could dysbiosis of inflammatory and anti-inflammatory gut bacteria have an implications in the development of type 2 diabetes? A pilot investigation","volume":"14","author":"Kulkarni","year":"2021","journal-title":"BMC Res Notes"},{"key":"2026090212264547600_bib40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41380-022-01841-y","article-title":"Gut microbiota regulates chronic ethanol exposure-induced depressive-like behavior through hippocampal NLRP3-mediated neuroinflammation","volume":"28","author":"Yao","year":"2023","journal-title":"Mol Psychiatry"},{"key":"2026090212264547600_bib41","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","article-title":"From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites","volume":"165","author":"Koh","year":"2016","journal-title":"Cell"}],"container-title":["Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/joe\/article-pdf\/doi\/10.1530\/JOE-26-0110\/524043\/joe-26-0110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/joe\/article-pdf\/doi\/10.1530\/JOE-26-0110\/524043\/joe-26-0110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:26:58Z","timestamp":1788366418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/joe\/article\/270\/3\/e260110\/78056\/Empagliflozin-improves-gut-microbial-disturbances"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/joe-26-0110","relation":{},"ISSN":["0022-0795","1479-6805"],"issn-type":[{"value":"0022-0795","type":"print"},{"value":"1479-6805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"e260110"}}